Explainable machine learning prediction of edema adverse events in patients treated with tepotinib

• Main Authors: Federico Amato (Author), Rainer Strotmann (Author), Roberto Castello (Author), Rolf Bruns (Author), Vishal Ghori (Author), Andreas Johne (Author), Karin Berghoff (Author), Karthik Venkatakrishnan (Author), Nadia Terranova (Author)
• Format: Book
• Published: Wiley, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Tepotinib is approved for the treatment of patients with non‐small‐cell lung cancer harboring MET exon 14 skipping alterations. While edema is the most prevalent adverse event (AE) and a known class effect of MET inhibitors including tepotinib, there is still limited understanding about the...